Does generative AI mean the “end of history” for pharmacovigilance automation? towards a framework for the future of human-AI systems
Frontiers in Drug Safety and Regulation · 18.08.2026 · 6
DOI: 10.3389/fdsfr.2026.1846339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Drug Safety and Regulation, online erschienen am 18.08.2026. Verfasst von Leihong Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, United States. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Toxicological Research.
Abstract (Originalsprache)
Introduction
Advances in generative artificial intelligence (AI), particularly large language models (LLMs), have sparked discussions in automating pharmacovigilance (PV) workflows. It remains unclear whether these technological advancements fundamentally change the prior conclusions that full automation of Individual Case Safety Report (ICSR) processing is not feasible.
Methods
This perspective examines recent developments in AI for PV and introduces a conceptual framework of “computable PV,” in which tasks are evaluated based on their computational tractability and suitability for automation.
Results
Routine, well-defined PV tasks, including completeness checks, detection of duplicated ICSRs, and structured information extraction, are increasingly amenable to automation. In contrast, complex activities such as case-level causality assessment remain difficult to formalize and continue to rely on expert judgment. The emergence of LLMs enables broader, cross-task capabilities compared to traditional task-specific, “small” models, but introduces challenges related to reliability, auditability, and governance. As a result, hybrid architecture combining large models, small models, and rule-based components is increasingly necessary.
Conclusion
Generative AI, as of today, does not signal full automation of PV but rather shifts toward hybrid human-AI systems. While AI can augment efficiency and support evidence synthesis, final decisions must remain under human oversight. Future PV systems should prioritize transparency, validation, and the integration of AI outputs into expert-driven decision-making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, United States.
- Offices of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
Förderung
- National Center for Toxicological Research
Zitieren
APA
Wu, L., Xu, J., Dang, O., & Ball, R. (2026). Does generative AI mean the “end of history” for pharmacovigilance automation? towards a framework for the future of human-AI systems. Frontiers in Drug Safety and Regulation, 6. https://doi.org/10.3389/fdsfr.2026.1846339
Vancouver
Wu L, Xu J, Dang O, Ball R. Does generative AI mean the “end of history” for pharmacovigilance automation? towards a framework for the future of human-AI systems. Frontiers in Drug Safety and Regulation. 2026;6. doi:10.3389/fdsfr.2026.1846339
BibTeX
@article{Wu2026,
author = {Wu, Leihong and Xu, Joshua and Dang, Oanh and Ball, Robert},
title = {Does generative AI mean the “end of history” for pharmacovigilance automation? towards a framework for the future of human-AI systems},
journal = {Frontiers in Drug Safety and Regulation},
year = {2026},
volume = {6},
doi = {10.3389/fdsfr.2026.1846339}
}
EUVIMED